Our efforts to address Parkinson’s Disease span not only research groups and faculties, but across international borders.

In some cases partnering with leading overseas organisations, our researchers are investigating everything from human circuits of learning and memory function (synaptic plasticity), to drug repurposing, to tailored medical solutions for individuals.

The work is so diverse, that even within singular projects there are complex combinations of expertise in neuroscience, molecular biology, biochemistry and neuro engineering. And while the impact is global, the footprint within Australia is considerable, including training approximately 85 per cent of deep brain stimulation (DBS) practitioners in the country.

Together, our researchers are combatting a disease which, according to a 2014 report by Parkinson’s Australia, is expected to increase by three times the rate of population growth in coming years.

Explore our groups

Securing better outcomes for Deep Brain Stimulation (DBS) patients
The Asia-Pacific Centre for Neuromodulation (APCN) is a world leader in the integration of research, education and clinical care. APCN has strong links with international research and clinical networks on Neuromodulation technology and procedures and is a leading data hub for the Asia-Pacific region.
Functional neuromodulation and novel therapeutics
Led by Susannah Tye, this group aims to understand why some individuals fail to improve in response to such therapies and to advance progress towards the discovery and development of novel treatments to help the large proportion of patients suffering from psychiatric disease.
Synaptic plasticity
The Sah laboratory uses electrophysiology and molecular techniques, in conjunction with behavioural studies, to understand the neural circuitry that underpins learning and memory formation.
Melatonin for insomnia in Parkinson's disease
Does melatonin assist patients with Parkinson’s Disease and insomnia to sleep better?
Fast-tracking new treatments for neurodegenerative diseases such as Parkinson’s disease
The Queensland Drug Repurposing Initiative (QDRI) investigates whether drugs already approved to treat other diseases can also help treat neurodegeneration.